Abstract 1814
Background
Tumor Treating Fields (TTFields) are intermediate frequency, alternating electric fields that non-invasively treat cancer. Transducer arrays positioned on the skin in proximity to the targeted tumor transmit TTFields. A post-hoc analysis [Ballo et al. Red Jour. 2019 In Press] has shown that increased patient usage (percent of time on active treatment) and intensity of TTFields delivery direct to the tumor improved survival. Optimal array positioning may enhance TTFields intensity at the tumor site to improve patient experience and survival. Minimization of array exposure area would enhance patient comfort levels and usage to improve survival. Optimizing TTFields delivery and distribution depends on array positioning and geometry, patient anatomy, and the heterogeneous electrical properties of different tissues. We present methodology to optimize TTFields delivery using numerical simulations.
Methods
TTFields delivery to the brain, lung, and abdomen utilizing representative computational models was investigated. The effects of transducer array size and position on field distribution within the phantoms was analyzed, and an approach to optimize TTFields delivery was developed.
Results
Field intensity was typically the greatest in between arrays, with larger arrays transmitting higher field power. Anatomical features, such as bones (spine) or a resection cavity significantly influenced field intensity within this region. A generalized methodology to optimize TTFields delivery for improved patient care was based on: (1) Striking a balance between maximal field intensity (largest arrays feasible) and minimal skin exposure to arrays in the disease area; (2) Positioning virtual arrays on a representative, computational patient model to test tumor localization between arrays, to simulate TTFields delivery to patient, and to assess optimal delivery; and (3) Applying an iterative algorithm to shift arrays around their initial positions until field intensity is maximized directly to the tumor bed.
Conclusions
A generalized treatment methodology as presented by these data will optimize TTFields delivery to the tumor site. Effective TTFields treatment planning is expected to improve patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novocure.
Funding
Novocure.
Disclosure
N. Urman: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. Z. Bomzon: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. H.S. Hershkovich: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E.D. Kirson: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. A. Naveh: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. R. Shamir: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E. Fedorov: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. C. Wenger: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. U. Weinberg: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract